CompletedNCT00088634
Official study titleA Double-blind Fixed-dose Study of Lurasidone (SM-13496) and Placebo in the Treatment of Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including BirminghamSchizophreniaMedication studyAges 18–64
- Countries
- United States
- Sponsor
- Sumitomo Pharma America, Inc.
CompletedNCT00827918
What is this study about?Researchers compared MK-8998, Comparator: Olanzapine and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–55
- Countries
- Sponsor
- Merck Sharp & Dohme LLC
CompletedNCT00088621
Official study titleAn Open-Label, Multicenter, Twelve-Month Study of Safety and Tolerability in the Treatment of Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including BirminghamSchizophreniaMedication studyAges 18–64
- Countries
- United States
- Sponsor
- Sumitomo Pharma America, Inc.
CompletedNCT03809325
Official study titleCross-sectional Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
This study has finished and is no longer accepting participants.
Multiple locations, including BrusselsSchizophreniaObservational studyAges 18+
- Countries
- France, United Kingdom, Belgium, + 4 others
- Sponsor
- Janssen-Cilag International NV
TerminatedNCT03892889
Official study titleA Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
This study ended early.
Multiple locations, including PhoenixSchizophreniaInterventional studyAges 18–65
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT02478827
Official study titleA Trial of Cognitive Training in Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including CalgarySchizophreniaBehavioural studyAges 18–65
- Countries
- Canada
- Sponsor
- University of Calgary
CompletedNCT01724476
Official study titleA Placebo-Controlled Trial of Folate With B12 in Patients With Schizophrenia With Residual Symptoms in Ethiopia
This study has finished and is no longer accepting participants.
In Addis AbabaSchizophreniaMedication studyAges 18–65
- Countries
- Ethiopia
- Sponsor
- Massachusetts General Hospital (Hospital / academic medical center)
CompletedNCT01606228
What is this study about?Researchers studied Paliperidone ER to find out how it affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–65
- Countries
- Sponsor
- Janssen Pharmaceutica
CompletedNCT07305779
Official study titleA Phase 1, Open-label, Single-sequence Pharmacokinetic Trial to Assess the Effect of a Single Oral Dose of SEP-380135 on the Potential for Cytochrome P4502D6 Mediated Drug-drug Interactions in Healthy Adults
This study has finished and is no longer accepting participants.
In Overland ParkSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT01566162
Official study titleA Twelve Week, Multicenter, Open Label Extension Study in Subjects With Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18+
- Countries
- United States, France, Italy, + 4 others
- Sponsor
- Sumitomo Pharma America, Inc.
CompletedNCT05210816
Official study titleThe Effect of Acceptance and Commitment Therapy on Psychotic Symptoms and Functioning Levels in Early Psychosis Patients
This study has finished and is no longer accepting participants.
In IstanbulSchizophreniaBehavioural studyAges 18–65
- Countries
- Türkiye
- Sponsor
- Saglik Bilimleri Universitesi
CompletedNCT01635075
This study has finished and is no longer accepting participants.
In ProvidenceSchizophreniaBehavioural studyAges 18–60
- Countries
- United States
- Sponsor
- Brown University